<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02417987</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2010-052a</org_study_id>
    <nct_id>NCT02417987</nct_id>
  </id_info>
  <brief_title>High Volume Injection or Autologous Conditioned Plasma (ACP) in Chronic Achilles Tendinopathy</brief_title>
  <official_title>High Volume Injection (HVI) or Autologous Conditioned Plasma (ACP) in Chronic Achilles Tendinopathy: A Randomized Controlled Double Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine patients with chronic Achilles Tendinopathy (AT) and to&#xD;
      compare the effect of high volume injection (HVI) or autologous conditioned plasma (ACP) in&#xD;
      combination with eccentric training to placebo treatment (sham treatment combined with&#xD;
      eccentric exercises).&#xD;
&#xD;
      Healthy males with AT will be randomly assigned to either 1) HVI (50 mls;10 mls 0.5%&#xD;
      bupivacaine hydrochloride and 20 mg of Depomedrol followed by 40 mls saline), 2) ACP (~ 4&#xD;
      mls) or 3) Placebo (Plc) treatment. All subjects will perform a 12-wk eccentric training&#xD;
      program and examinations will be done at baseline (before treatment) with follow-ups after 6&#xD;
      weeks, 12 weeks and again after 24 weeks prior to baseline to see any possible changes and&#xD;
      differences between groups (HVI, ACP and Plc)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Achilles tendinopathy (AT) is a common and impairing disorder. Only sparse scientific&#xD;
      evidence exists for the present used treatments and no golden standard treatment exists so&#xD;
      far.&#xD;
&#xD;
      Aim: The aim of the study is in AT patients to examine and compare the effect of high volume&#xD;
      injection (HVI) or autologous conditioned plasma (ACP) in combination with eccentric training&#xD;
      to placebo treatment (sham treatment and eccentric exercises).&#xD;
&#xD;
      Materials and methods: Healthy males (21-59 years; n=60) with AT is randomly assigned to&#xD;
      either 1) HVI (50 mls;10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol followed&#xD;
      by 40 mls saline), 2) ACP (~ 4 mls) or 3) placebo (Plc) treatment. Participants will treated&#xD;
      on 4 successive occasions with 2 weeks (wks) interval (HVI will only be injected once at&#xD;
      baseline, the 3 following injections will be placebo). The injections will be performed under&#xD;
      ultrasound guidance. All subjects will undergo a 12-wk eccentric training program. Clinical&#xD;
      effects will be assessed as changes in symptoms and pain (VISA-A and VAS score), tendon&#xD;
      ultrasound thickness and muscle function (one-legged heel-rise test). All outcome measures&#xD;
      will be recorded at baseline and again at 6 weeks, 12 week and 6 month follow-up.&#xD;
&#xD;
      Results: Will se the changes and differences between groups (HVI, ACP and Placebo) in VISA-A&#xD;
      scores, VAS scores, ultrasound (tendon thickness) and muscle function.&#xD;
&#xD;
      Statistics: All data will be analyzed in SigmaPlot v11 using two-way repeated measures ANOVA&#xD;
      with Student-Newman-Keuls Post-hoc test. This is used to see changes over time in all groups&#xD;
      (time effect) and differences between groups within time-points (group effect). All data will&#xD;
      be presented as mean Â± SEM time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VISA-A score</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks and 24 weeks</time_frame>
    <description>See the changes in VISA-A score over time due to the effect of treatment between groups (HVI, ACP and Plc)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS score</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks and 24 weeks</time_frame>
    <description>See the changes in VAS score over time due to the effect of treatment between groups (HVI, ACP and Plc)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound tendon thickness and doppler activity</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks and 24 weeks</time_frame>
    <description>See the changes in tendon thickness over time due to the effect of treatment between groups (HVI, ACP and Plc)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Muscle function performance test (total workload)</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks and 24 weeks</time_frame>
    <description>See the muscle function performance (total workload- heel raise test) performed over time due to the effect of treatment between groups (HVI, ACP and Plc)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>High Volume injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A total volume of 50 ml:&#xD;
10 mls 0.5% bupivacaine hydrochloride and&#xD;
20 mg of Depomedrol (hydrocortisone)&#xD;
40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous conditioned plasma (ACP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).&#xD;
The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A few drops of saline is injected in the soft tissue away from the tendon.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon</description>
    <arm_group_label>Autologous conditioned plasma (ACP)</arm_group_label>
    <arm_group_label>High Volume injection</arm_group_label>
    <other_name>Sham treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Volume injection</intervention_name>
    <description>Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon</description>
    <arm_group_label>Autologous conditioned plasma (ACP)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>HVI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous conditioned plasma (ACP)</intervention_name>
    <description>Injection with 4 mls of ACP around the tendon</description>
    <arm_group_label>High Volume injection</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Platelet-rich plasma (PRP)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinically and ultrasound diagnosed unilateral midt-tendinous achilles tendinopathy&#xD;
&#xD;
          -  Symptoms &gt; 3 month&#xD;
&#xD;
          -  No steroid injections &lt; 6 month&#xD;
&#xD;
          -  60 males with BMI &lt;30 between 18-60 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral achilles tendinopathy&#xD;
&#xD;
          -  Insertional tendinopathy&#xD;
&#xD;
          -  Steroid injections &lt; 6 month&#xD;
&#xD;
          -  Diabetes or cardiovascular disease&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Treatment with fluoroquinolones &lt; 6 month&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kjaer, Dr. Med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Sportsmedicine Copenhagen, Bispebjerg Hospital</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Anders Ploug Boesen</investigator_full_name>
    <investigator_title>MD, PhD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

